JAK2 V617F mutation is found in patients with blood related disease such as Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. Ruxolitinib is effective as a JAK Inhibitor, so that it is a prognostic factor to determine drug response.
JAK2 V617F mutation detection makes easy to classify patients with MPD (Myeloproliferative Disease) as three levels of diagnostic certainty (possible, probable and definite) and to determine which signal transduction therapy is suitable for each patients. In addition, testing for JAK2 V617F mutation has been recommended as clinical tests by WHO(World Health Organization).
CAT NO.
PNAC-6001 (size: 25 tests)
JAK2 V617F mutation can be detected by PNAClamp™ JAK2 Mutation Detection Kit.
|
Mutations
|
Size
|
|
Exon 14
|
25 tests
|
|
V617F (1849G>T)
|
